Provider review
GOAL.MD Review: Careful About Drugs, Careless About Regulators
GOAL.MD rebuilt its pricing this month, and the new shape is better than the old one: every dose costs the same, the term is what moves the number, and the total you pay upfront is printed beside the per-month equivalent. The claim it still gets wrong is regulatory. It says its pharmacies are “FDA-monitored”, and FDA does not monitor pharmacies.
Correction, August 2026
This review previously said: “It makes no efficacy claim at all — no percentage, no trial reference, no outcome promise. […] The monthly total roughly doubles across an ordinary titration, from $294 at 0.25 mg to $594 at 2 mg.”
That was wrong. GOAL.MD rebuilt its pricing between 14 and 26 August 2026, and added outcome copy at the same time. The dose-priced table this review reproduced — $199 / $349 / $499 of medication plus a $95 physician-supervision fee — is no longer on the site. Pricing is now all-inclusive and set by plan term, with the site stating explicitly "Every prescribed dosage is included at the same price" and "No surprise upcharges at higher doses". A finding about escalation across a titration cannot survive a seller that has removed the escalation. On the efficacy half: six patient testimonials with pound figures, a coaching panel citing a 2025 meta-analysis for "15+ lbs additional weight loss", and two uncited statistics inside the intake are all outcome claims, and the original sentence said there were none.
It now says: Re-read and walked 2026-08-26. Semaglutide is $99 a month equivalent on a $1,188 charge taken upfront for twelve months, $139 on $834 for six, $159 on $477 for three, or $179 month to month — every dose from 0.25 mg to 2.5 mg at the same price. Tirzepatide runs $159 / $179 / $199 / $249 on the same ladder, flat from 2.5 mg to 15 mg. The supervision fee this review recorded in August still exists, but now only on the brand-name route through LillyDirect and NovoCare, where it is $95 a month. GOAL.MD does make efficacy claims, and the semaglutide row is graded "overstates" rather than "matches" as a result. The finding this review exists for is unchanged and was re-read on the live page: "Only FDA-monitored 503A/B pharmacies" still describes an oversight FDA does not perform.
Prices every dose the same and prints the upfront total beside the monthly equivalent, which is better arithmetic than most of this category manages — then invents an FDA oversight of pharmacies that does not exist and sources its best outcome number to a meta-analysis it does not name.
Worth trusting if
- You want a flat price across a titration — every dose is the same figure, and the site says so in as many words
- You want to see the whole charge before you agree to it, because the prepaid total is printed beside the per-month equivalent
- You want brand and compounded routes described separately, with the brand-name fee stated on its own
Be skeptical if
- You are relying on “FDA-monitored” as an assurance about the pharmacy, because no such status exists
- You want the pharmacy named or a test result published rather than a “third-party quality testing” badge
- You cannot pay a term upfront, because the cheapest rate is a single charge for twelve months and month-to-month costs nearly twice as much
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens goal.md. A link is not a recommendation to take anything.
Provenance
What GOAL.MD actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Personalized Semaglutide Injection (all-inclusive) — All-inclusive — physician, medication, nutrition coaching and shipping — and priced by TERM rather than by dose: $99 a month equivalent on a $1,188 charge taken upfront for twelve months, $139 on $834 for six, $159 on $477 for three, or $179 month to month. Every dose from 0.25 mg to 2.5 mg is the same price. Read 2026-08-26; on 2026-08-14 this review recorded a different structure entirely — dose-priced medication plus a $95/mo supervision fee — see the correction.
- Personalized Tirzepatide Injection (all-inclusive) — $159 a month equivalent on a $1,908 charge taken upfront for twelve months, $179 on $1,074 for six, $199 on $597 for three, or $249 month to month. Every dose from 2.5 mg to 15 mg is the same price. Read 2026-08-26.
- Sermorelin — For muscle support & recovery — $179 a month equivalent on a $537 charge taken upfront for three months, or $199 month to month. Read 2026-08-26. The site states "No memberships. No auto-billing" and describes the bundle as "same medication, lower per-month price", so the $179 figure is arithmetic on a single charge rather than an amount that lands each month.
- NAD+ — For energy and longevity — $249 a month, stated as covering "All dosages, no hidden fees". Read 2026-08-26. This is the most expensive single product GOAL.MD sells month to month — more than a month of semaglutide or tirzepatide on any of their four terms.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 4 products reviewed here. The evidence belongs to the molecule, not to GOAL.MD.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from GOAL.MD’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Personalized Semaglutide Injection (all-inclusive)Semaglutide · Compounded (503A)Claim reaches past the trials
“GOAL.MD now provides access to brand-name GLP-1s — Zepbound, Wegovy, and Ozempic — alongside our personalized formulations. […] See exactly what you'll pay — no hidden fees, no surprises, and never any auto-billing. […] All-inclusive — physician, medication, nutrition coaching, and shipping. […] Every prescribed dosage is included at the same price. […] Only FDA-monitored 503A/B pharmacies. Safe, legal, properly compounded medications. […] Compounded medications are personalized formulations prepared by licensed U.S. 503A or 503B compounding pharmacies based on a physician's prescription for an individual patient's specific clinical needs. Compounded medications are not FDA-approved.”
Read on the GOAL.MD site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg over 68 weeks — the evidence for the FDA-approved product GOAL.MD says is bought separately through manufacturer programs, not for the personalized formulation it compounds.
Re-read 2026-08-26, and this row is graded harder than it was on 14 August — see the correction at the top of the page. Two things are still right and worth saying first. The phrase "FDA-approved medications" is used correctly: it describes branded Ozempic, Wegovy and Zepbound obtained through LillyDirect and NovoCare, and the footnote says those "require a separate GOAL.MD physician fee" rather than presenting them as GOAL.MD's own product. And the site now carries a real compounding disclosure in its footer — "Compounded medications are not FDA-approved" — which it did not carry when this review was written. What has changed for the worse is that the site is no longer claim-free. Six testimonials on the homepage carry pound figures up to −175; a coaching panel asserts "15+ lbs additional weight loss with coaching", sourced only to "meta-analysis of randomized controlled trials, eClinicalMedicine 2025" with no title, authors or identifier; and the second screen of the walked intake asserts that "Research shows that 80% of people are more attracted to those with leaner, stronger appearances" and "Over 90% of patients report higher self-confidence after achieving visible weight loss results", neither cited to anything. And the regulatory error is unchanged: "Only FDA-monitored 503A/B pharmacies" describes an oversight that does not exist. FDA does not monitor, license or approve compounding pharmacies; state boards license and inspect 503A compounders, and 503B outsourcing facilities register with FDA without being approved by it. "Safe, legal, properly compounded" in the same breath compounds the impression of an authority nobody granted.1
Personalized Tirzepatide Injection (all-inclusive)Tirzepatide · Compounded (503A)Claim matches the trials
“Tirzepatide now starting at $159/month. The longer you commit, the more you save. Personalized Tirzepatide Injection · all-inclusive […] Every dosage is included at the same price […] ✓ Physician · ✓ Medication · ✓ Nutrition coaching · ✓ Free shipping — included with every term”
Read on the GOAL.MD site, August 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tirzepatide over 72 weeks in adults with obesity or overweight — the approved product at label doses, not a compounded personalized formulation.
No efficacy figure is attached to tirzepatide specifically anywhere on the site. What the tirzepatide block claims is commercial — a term ladder, a flat price across the 2.5 mg to 15 mg range, and four things included — and all four are checkable on the page. That is the right amount to say about a compounded copy of a drug whose trials tested something else. The same two caveats apply as everywhere: the personalized formulation is not the product SURMOUNT-1 tested, and the pharmacy claim over the page — "Only FDA-monitored 503A/B pharmacies" — is not a real designation.2
Sermorelin — For muscle support & recoverySermorelin · Compounded (503A)Claim reaches past the trials
“Growth hormone-releasing peptide for muscle growth and recovery. […] Supports muscle growth and recovery. May improve sleep quality. […] Support your body's own growth hormone — not replace it. […] Lean muscle & body composition — May support lean body mass and strength when paired with consistent resistance training and adequate protein intake. Deeper, more restorative sleep — GHRH peptides like Sermorelin act on the pituitary at night — many patients report falling asleep faster and waking more rested within the first few weeks. […] Skin tone & elasticity — Patients commonly report subtle improvements in skin tone, hydration, and firmness over 3–6 months of consistent therapy.”
Read on the GOAL.MD site, August 2026
No trial for this use
What the trials show for Sermorelin
Searched 26 August 2026, and the registry result is the one to lead with: ClinicalTrials.gov holds 21 completed studies matching sermorelin by intervention, and not one of them actually gave sermorelin. Reading the intervention field of all 21, they are tesamorelin or TH9507 (nine of them), unspecified GHRH used as a diagnostic stimulation test, full-length GHRH 1-44, a long-acting growth hormone, and octreotide. There is no completed registry record of sermorelin itself. PubMed returns 19 records for sermorelin restricted to the randomized-controlled-trial publication type, the most recent published in August 2005. Narrowing those to ones that also mention muscle, body composition, lean mass, sleep, recovery or skin leaves three: a 1993 study of galanin in Cushing's disease, a 1992 study measuring growth hormone and IGF-I levels in older men, and a 1997 placebo-controlled trial in 19 adults aged 55 to 71 of a modified GHRH(1-29) analog rather than sermorelin itself. That 1997 trial is the closest thing that exists to evidence for this product, and what it found is set out in the verdict below. Restricting the same search to the word sermorelin in title or abstract returns zero, which is the search error this site has already published a correction about: the trial literature calls the molecule GHRH(1-29)-NH2, so a title-and-abstract restriction deletes the entire record set by construction.
GOAL.MD hedges more carefully than most sellers of this molecule — "may support", "patients commonly report" — and two of its sentences are simply true: sermorelin is a GHRH analog, and it does prompt the pituitary to release growth hormone rather than replacing it. The problem is the one unhedged line in the benefits list, "Supports muscle growth and recovery", and the sleep claim beside it. Take them against the single most relevant randomized trial, from 1997: 19 adults aged 55 to 71 self-injected a GHRH(1-29) analog nightly for 16 weeks against placebo. It increased lean body mass in the nine men and not in the ten women, changed nothing else in body composition, left body weight unaffected — and it measured sleep quality directly and reported it unaffected in both sexes. So the muscle claim rests on nine men in a 1997 study of a molecule that is not quite this one, and the sleep claim is not merely untested but points against the nearest thing to a measurement. The one benefit that trial did find in both sexes is the one GOAL.MD words most tentatively: skin thickness increased. Two further things a buyer should know. Sermorelin has no completed registry study of its own, and GOAL.MD's own evidence library at /peptides does not carry a sermorelin page, so the company publishes physician-reviewed evidence summaries for 20 peptides and not for the one on this product page.3,4
NAD+ — For energy and longevityNicotinamide adenine dinucleotide (NAD+) · Compounded (503A)No trial supports this claim
“NAD+ coenzyme therapy for cellular energy, mental clarity, and healthy aging. […] Supports cellular energy production. May improve mental clarity. […] Research shows NAD+ levels tend to decline as we age. NAD+ therapy is designed to help replenish this essential coenzyme — supporting energy metabolism, mental clarity, and healthy cellular function as part of a physician-guided protocol. […] DNA maintenance — NAD+ fuels enzymes involved in the body's natural DNA-repair and cellular-housekeeping processes. […] WEEKS 2–4 Settling in — As levels are replenished consistently, many patients report steadier daytime energy and improved mental clarity.”
Read on the GOAL.MD site, August 2026
No trial for this use
Searched 26 August 2026. A PubMed search for nicotinamide adenine dinucleotide or NAD+ in title or abstract, combined with an injected route — subcutaneous, injection or intravenous — and restricted to the randomized-controlled-trial publication type returns four records, and opening all four is the whole exercise. Only one of them administers NAD+ by an injected route: a 2026 randomized placebo-controlled trial in heart failure caused by ischemic cardiomyopathy. The other three are a 2012 phase 1 trial of a SIRT1 activator, a 2011 hypertonic-saline heart-failure study, and a 2006 paper on how fast the blood clears ethanol after intravenous amino acids. Nothing in that set measures energy, mental clarity, DNA repair or healthy aging in adults who do not have heart failure. The same search shape run for tirzepatide returns 133 randomized papers and an invented drug name returns none, so the query works.
The biochemistry on this page is accurate and unusually well written. NAD+ is a coenzyme in every cell, it is central to turning food into ATP, it does fuel enzymes involved in DNA repair, and its levels do fall with age — all four of those sentences would survive a textbook. None of them is the claim a buyer is being charged for. The claim being charged for is that injecting it produces energy, mental clarity and healthy aging in a person, and the randomized literature contains one trial that gives injected NAD+ to anybody, in ischemic heart failure. Watch how the page moves between the two registers: "Research shows NAD+ levels tend to decline as we age" is a fact about biology, and the next clause — "NAD+ therapy is designed to help replenish this essential coenzyme" — is a fact about intent, not about outcome. Then a three-stage timeline promises steadier energy and improved mental clarity by weeks 2 to 4. Nothing measured that. The same applies to "May improve mental clarity", which is the one benefit stated on the buy panel and has no trial behind it in this route at any dose.5,6
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named. GOAL.MD says prescriptions "are supplied by our independent licensed pharmacy partners" and claims "Only FDA-monitored 503A/B pharmacies", but identifies none — so the category claim cannot be checked, and the category itself is wrong. Two things have improved since this review was first written, and both are on the same page as the error. The footer now carries a full compounding disclosure: "Compounded medications are personalized formulations prepared by licensed U.S. 503A or 503B compounding pharmacies based on a physician's prescription for an individual patient's specific clinical needs. Compounded medications are not FDA-approved." And the brand-name route is separated cleanly — Ozempic, Wegovy and Zepbound are described as accessed "through manufacturer programs (LillyDirect/NovoCare)" with a stated disclaimer that "GOAL.MD is not affiliated with Novo Nordisk, Eli Lilly, or their programs". It also states, usefully, that the pictured vial and packaging "will look different" from the illustration, which is the same confusion FDA cited other companies in this batch over.
Read on the GOAL.MD site, August 2026.
Quality
Third-party testing, and what is published
Yes
Describes a testing regime
A described program, not a document.
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
A testing claim now exists where none did on 14 August: the badge strip beneath the product grid reads "Third-party quality testing". That is the whole of it — no laboratory is named, no assay is described, no lot is referenced, no frequency is given and no certificate of analysis is published or offered. Beside it sits "Safe, legal, properly compounded medications", which asserts a conclusion rather than showing a result, attached to the incorrect regulatory description "Only FDA-monitored 503A/B pharmacies". A three-word badge is a claim that testing happens; it is not a test result, and the distinction is the whole reason this site records the two separately.
Read on the GOAL.MD site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
48 states, as a count rather than a list. The homepage FAQ answers "Which states are eligible for GLP-1 treatment programs?" with: "We currently serve patients in 48 states across the US. Our telehealth platform allows you to receive care from licensed physicians no matter where you're located. Contact us to confirm availability in your specific state." That answer sits behind a closed accordion and had to be clicked open to read. Forty-eight means two are excluded, and neither the forty-eight nor the two is named — so this review names no excluded states, because naming them would mean inventing them, not because none exist. A "Medicare GLP-1 Bridge" is advertised for eligible members without enumerating jurisdictions.
Read the full licensing claim
Only FDA-monitored 503A/B pharmacies. Safe, legal, properly compounded medications.
Read on the GOAL.MD site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with GOAL.MD
We went through GOAL.MD’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Read the whole price ladder on the homepage. Both molecules, all four terms, the prepaid total and the month-to-month rate are published before anything is asked.
- Press Start Semaglutide. A new tab opens at /intake with the plan preselected.
- Say what brings you to GOAL.MD: weight loss, energy and longevity (NAD+), muscle and recovery (sermorelin peptide therapy), several, or undecided.
- Say which of physical health, appearance or mental health is your priority.
- Read a screen of statistics about attractiveness and self-confidence, then give your sex assigned at birth.
- Read a patient testimonial reporting 32 pounds lost in four months, then enter height and weight.
- Give a goal weight, read a screen arguing that weight is biology rather than willpower, and say whether you already take a GLP-1.
- Give a date of birth — the screen states you must be between 18 and 75 to qualify.
- The medical screening begins: diabetes, pancreatitis, pregnancy. The walk stopped at that screen.
- Every price is public before intake. Semaglutide is $99 a month equivalent on $1,188 prepaid for twelve months, $139 on $834 for six, $159 on $477 for three, and $179 month to month. Tirzepatide is $159 / $179 / $199 / $249 on totals of $1,908, $1,074 and $597.
- A prepaid plan is one charge, not a subscription. The site says so — "Prepaid plans are charged upfront — not a subscription" — so the per-month figure is arithmetic on a single payment rather than an amount that lands each month.
- The saving for committing is large and stated: twelve months of semaglutide costs $80 a month less than paying month to month, and twelve months of tirzepatide $90 a month less.
- Two further options are listed with no term ladder attached: Semaglutide Micro-Dose from $197 a month and GLP-1 Synergy from $597 a month.
- The brand-name route is priced separately and the fee is stated: prices come from LillyDirect or NovoCare and "require a separate GOAL.MD physician fee of $95/mo".
- Dose does not change the price. "Every prescribed dosage is included at the same price" is printed under both ladders, with the dose bands listed — 0.25 mg to 2.5 mg for semaglutide, 2.5 mg to 15 mg for tirzepatide.
- The intake is a hosted flow inside a shadow DOM, so its text does not appear in the page's own body copy. Two uncited statistics sit on its second screen: that 80% of people are more attracted to leaner appearances, and that over 90% of patients report higher self-confidence after visible weight loss.
- The first question offers sermorelin peptide therapy and NAD+ as alternatives to weight loss, which is where the peptide side of this business actually starts.
- The walk is partial in as many words: it stopped at the first medical-screening screen, before any health condition was answered and long before checkout. Nothing was bought and no account was created.
- GOAL.MD makes a specific promise about billing on the same page: "never any auto-billing", and "Other telehealth companies auto-bill your card month after month. Some require 14-30 days notice to cancel… Not us. We ask. You decide."
GOAL.MD support
- Phone
- 800.674.2855
- Hours
- Monday to Friday, 9am–5pm Central
Assessment
What holds up, and what does not
- Every dose costs the same. "Every prescribed dosage is included at the same price" is printed under both ladders, with the dose bands named — which removes the escalation most of this category builds in.
- The prepaid total is printed beside the per-month equivalent, so the number that will actually leave your account is on the page.
- It uses "FDA-approved medications" correctly, describing branded drugs accessed through LillyDirect and NovoCare, and states the separate physician fee those carry.
Show 5 more
- It disclaims affiliation with Novo Nordisk and Eli Lilly by name rather than trading on the association.
- The footer now carries a full compounding disclosure ending "Compounded medications are not FDA-approved", which the site did not carry two weeks ago.
- It says the pictured vial and packaging will look different from the illustration — the exact confusion FDA cited other companies over.
- It states "there's never any auto-billing" and explains what it is contrasting itself with, rather than leaving a reassurance to float.
- Two published phone numbers, stated hours and a support address, all in the footer.
- "Only FDA-monitored 503A/B pharmacies" describes an oversight that does not exist. FDA does not monitor, license or approve compounding pharmacies; state boards license and inspect them.
- "Safe, legal, properly compounded medications" asserts a conclusion about quality with no test result behind it.
- "Third-party quality testing" is a three-word badge with no laboratory, no assay, no lot and no certificate attached.
Show 9 more
- No pharmacy is named, so even the correct part of the licensing claim cannot be checked.
- The best outcome number on the site — "15+ lbs additional weight loss with coaching" — is sourced only to "meta-analysis of randomized controlled trials, eClinicalMedicine 2025", with no title, authors or identifier a reader could look up.
- Two statistics inside the intake — that 80% of people are more attracted to leaner appearances, and that over 90% of patients report higher self-confidence after visible weight loss — carry no source at all.
- The cheapest rate is a single upfront charge for a year: $1,188 for semaglutide or $1,908 for tirzepatide, against $179 and $249 a month for the flexibility.
- The same figure means different things across the two ladders — $159 is three months of semaglutide and twelve months of tirzepatide; $179 is a month of semaglutide and six months of tirzepatide.
- Its sermorelin page says "May improve sleep quality" and that "many patients report falling asleep faster". The closest randomized trial to this product measured sleep quality directly and reported it unaffected — so that claim is not untested, it is tested and unmet.
- NAD+ at $249 a month is the most expensive thing GOAL.MD sells month to month, and one randomized trial has ever given injected NAD+ to anybody — in heart failure. The page promises "steadier daytime energy and improved mental clarity" by weeks 2 to 4.
- It publishes physician-reviewed evidence pages for 20 peptides at /peptides and none for sermorelin, the peptide it actually sells.
- Coverage is published as a count, not a list: "we currently serve patients in 48 states", behind a closed accordion, with neither the forty-eight nor the two exclusions named and "contact us to confirm" in place of a checker.
Verdict
The bottom line
On money GOAL.MD is now one of the clearer sellers in this category: one price per molecule per term, every dose the same, and the upfront total printed where you can see it. On the pharmacy it is not. "FDA-monitored" is not a thing, no facility is named, and "third-party quality testing" is a badge rather than a result. Ask who compounds it, and for the certificate covering your lot.
Opens goal.md. A link is not a recommendation to take anything.
The pricing changed, and it changed for the better
Two weeks ago this review printed a table of GOAL.MD's dose-priced medication with a $95 physician fee added at every tier, and made the point that an ordinary titration roughly doubled the bill.
That table is gone. On 26 August 2026 the site prices by term, not by dose, and says so:
"Every prescribed dosage is included at the same price."
"No hidden fees. No surprise upcharges at higher doses."
| Semaglutide | Per month | Charged | |---|---|---| | 12 months prepaid | $99 | $1,188 upfront | | 6 months prepaid | $139 | $834 upfront | | 3 months prepaid | $159 | $477 upfront | | Month to month | $179 | monthly |
| Tirzepatide | Per month | Charged | |---|---|---| | 12 months prepaid | $159 | $1,908 upfront | | 6 months prepaid | $179 | $1,074 upfront | | 3 months prepaid | $199 | $597 upfront | | Month to month | $249 | monthly |
Both ladders are all-inclusive — physician, medication, nutrition coaching and shipping — and both list the dose bands the flat price covers: 0.25 mg to 2.5 mg, and 2.5 mg to 15 mg.
Read the second column carefully. A "per month" figure on a prepaid plan is arithmetic on one charge, and GOAL.MD says so rather than hiding it: "Prepaid plans are charged upfront — not a subscription." The cheapest way to buy semaglutide here is to hand over $1,188 on day one.
The $95 fee still exists. It has moved: brand-name Ozempic, Wegovy and Zepbound are accessed through LillyDirect or NovoCare and "require a separate GOAL.MD physician fee of $95/mo".
One quiet trap in the new ladders: the same number means different things. $159 is three months of semaglutide and twelve months of tirzepatide. $179 is one month of semaglutide and six months of tirzepatide.
Full analysis — 4 more sectionsThe claim it still gets wrong · It is no longer claim-free · The peptides, graded · What is missing
The claim it still gets wrong
"Only FDA-monitored 503A/B pharmacies."
Still on the homepage on 26 August 2026, under a heading that reads "LegitScript Certified".
FDA does not monitor compounding pharmacies. It does not license them or approve them either. State boards of pharmacy license and inspect 503A compounders. 503B outsourcing facilities register with FDA and are subject to inspection, but registration is not approval and FDA does not "monitor" them in the sense this sentence implies.
Adjacent to it: "Safe, legal, properly compounded medications." That is a conclusion. What sits under it now is a three-word badge — "Third-party quality testing" — with no laboratory, no assay, no lot number and no certificate.
The odd part is that the correct sentence is on the same page. GOAL.MD's footer now carries a genuine compounding disclosure it did not carry a fortnight ago:
"Compounded medications are personalized formulations prepared by licensed U.S. 503A or 503B compounding pharmacies based on a physician's prescription… Compounded medications are not FDA-approved."
A company that can write that paragraph knows what 503A and 503B are. The badge four screens above it says something the paragraph contradicts.
It is no longer claim-free
The other thing this review has to correct is that GOAL.MD used to assert nothing about outcomes. It now does.
Six testimonials on the homepage carry pound figures — −70, −57, −50, −45, and one at −175. The coaching panel makes the most specific claim on the site:
"15+ lbs additional weight loss with coaching … Based on meta-analysis of randomized controlled trials, eClinicalMedicine 2025"
A journal and a year, with no title, no authors and no identifier. That is a citation shaped like a citation, and a reader cannot follow it.
Inside the intake — a hosted flow whose text does not appear in the page's own body copy — the second screen asserts that "Research shows that 80% of people are more attracted to those with leaner, stronger appearances" and that "Over 90% of patients report higher self-confidence after achieving visible weight loss results." Neither carries any source.
The trials behind semaglutide and tirzepatide are real. 1 2 None of the three sentences above is drawn from them.
The peptides, graded
GOAL.MD's navigation now carries a Peptides column, and it sells Sermorelin "for muscle support & recovery" at $179 a month on a three-month charge and NAD+ "for energy and longevity" at $249 a month, both marked Rx only. The intake's first question offers "Muscle & Recovery — Sermorelin peptide therapy" and "Energy & Longevity — NAD+ therapy" as alternatives to weight loss. Both are graded above; here is what the searching actually turned up.
The sermorelin count that means nothing
Search ClinicalTrials.gov for sermorelin and you get 21 completed studies. That number is worthless, and the reason is worth a paragraph.
Open all 21 and read the field that records what participants were actually given. Nine of them administered tesamorelin or TH9507 — a different molecule, in HIV patients. Several used unspecified "GHRH" as a diagnostic stimulation test, which is a fifteen-minute procedure to see whether a pituitary responds, not a treatment. One used full-length GHRH 1-44, one a long-acting growth hormone, one octreotide. Not one of the 21 gave anybody sermorelin. 3
The published literature is thinner still, and its trap is the opposite one. Searching PubMed for sermorelin restricted to randomized controlled trials returns 19 records — but restrict that same search to the title and abstract and it returns zero, because the trial literature calls the molecule GHRH(1-29)-NH2 and almost never prints the brand name. This site has published a correction about exactly that error before, and it is the reason the number above is 19 and not nothing.
What the closest trial actually measured
Of those 19, three touch anything GOAL.MD sells this for. One is about galanin in Cushing's disease. One measured hormone levels in old men. The third is the trial that matters, from 1997: nineteen adults aged 55 to 71, self-injecting nightly for sixteen weeks against placebo. 4
Read its results against the product page, line by line:
| GOAL.MD says | The 1997 trial found | |---|---| | "Supports muscle growth and recovery" | Lean body mass rose in the nine men only, not in the ten women | | "May improve sleep quality" · "many patients report falling asleep faster" | "Sleep quality was unaffected in both genders" | | "Skin tone & elasticity" (the most tentative claim on the page) | Skin thickness rose significantly in both | | "Metabolic health… lean mass to fat mass" | No other change in body composition; body weight unaffected |
That is a more interesting result than a bare absence, and it cuts both ways. The claim GOAL.MD words most cautiously is the one the evidence best supports. The claim it states flatly in its benefits list rests on nine men in a study from 1997. And the sleep promise is not merely untested — it was measured, and it was not found.
One caveat this review will not skip, because it is the same kind of care this page is asking of GOAL.MD: the 1997 trial used a norleucine-substituted GHRH(1-29) analog, not sermorelin itself. It is the nearest evidence there is. It is not evidence about this exact molecule, because there isn't any.
NAD+ at $249 a month
The most expensive product GOAL.MD sells month to month — more than a month of semaglutide or tirzepatide on any term — and the one with the least behind it.
Four randomized trials in the literature mention NAD+ with an injected route. One of them actually gives it, in heart failure caused by ischemic cardiomyopathy. The other three are a phase 1 trial of a different compound, a hypertonic-saline heart-failure study, and a paper about how fast blood clears alcohol. 5 6
The page is worth reading closely for how it moves between registers. "NAD+ is a coenzyme present in every living cell" — true. "Research shows NAD+ levels tend to decline as we age" — true. "NAD+ therapy is designed to help replenish this essential coenzyme" — a statement about intent. And then a three-stage timeline in which "many patients report steadier daytime energy and improved mental clarity" by weeks 2 to 4. Each sentence is defensible on its own; the sequence delivers a reader to a conclusion nobody measured.
The part GOAL.MD gets right, on the same site
Its `/peptides` section is genuinely good, and saying so is not a courtesy. Twenty ingredient pages, each physician- and compliance-reviewed with named reviewers and a review date, plus a machine-readable file that labels each substance's regulatory status: tesamorelin, oxytocin and PT-141 as "FDA-approved for a specific indication", and BPC-157, CJC-1295, ipamorelin, MOTS-c, epitalon, TB-500 and eleven others as "Investigational". Its own usage notes warn that regulatory labels are per ingredient and must not be rolled up into a claim of FDA approval, and state plainly: "Compounded preparations are not FDA-approved."
That is better regulatory writing than this review has found anywhere else in the category, and it sits on the same domain as a badge reading "FDA-monitored 503A/B pharmacies".
Two gaps in it, though. Nothing in that section can be ordered — it is explicitly education-only — so a reader who arrives at the product pages never meets it. And sermorelin is not one of the twenty. GOAL.MD publishes a reviewed evidence page for nineteen peptides it does not sell and none for the one it does.
What is missing
No pharmacy named. No certificate of analysis.
On states, GOAL.MD gives a number and not a list. Click the FAQ accordion open and it says:
"We currently serve patients in 48 states across the US… Contact us to confirm availability in your specific state."
Forty-eight means two are excluded. Neither the forty-eight nor the two is named, there is no state checker, and the answer is behind a closed accordion rather than on the page. This review names no excluded states, because naming them would mean inventing them — not because none exist, since the count says two do.
One thing the accordions do answer well: "Are medications included in my treatment plan?" gets "Yes! All of our treatment plans include your prescribed medications, physician consultations, ongoing monitoring, and free expedited shipping directly to your door. There are no hidden fees or additional pharmacy costs." That is the all-inclusive claim stated plainly, and it matches the ladders.
Questions
Frequently asked questions
What does GOAL.MD cost?
It depends entirely on the term, and not at all on the dose. Semaglutide is $99 a month equivalent on a $1,188 charge taken upfront for twelve months, $139 on $834 for six, $159 on $477 for three, or $179 month to month. Tirzepatide is $159 / $179 / $199 / $249 on the same ladder. All four figures are all-inclusive — physician, medication, nutrition coaching and shipping — and the site states that every dose is included at the same price, 0.25 mg to 2.5 mg for semaglutide and 2.5 mg to 15 mg for tirzepatide. The prepaid plans are a single charge rather than a subscription, which GOAL.MD says plainly. Brand-name Ozempic, Wegovy and Zepbound run through manufacturer programs and carry a separate $95/mo physician fee. An earlier version of this review described a dose-priced structure; the correction is at the top of the page.
Are GOAL.MD's pharmacies FDA-monitored?
No, and no pharmacy is. FDA does not monitor, license or approve compounding pharmacies. State boards of pharmacy license and inspect 503A compounders; 503B outsourcing facilities register with FDA, but registration is not approval. Compounded drugs are not FDA-approved either — a point GOAL.MD's own footer now makes correctly, on the same page as the badge that gets it wrong.
Does GOAL.MD claim a particular weight loss?
It does now, which is a change since this review was first written. Six homepage testimonials carry pound figures up to −175, and a coaching panel claims "15+ lbs additional weight loss with coaching", sourced only to "meta-analysis of randomized controlled trials, eClinicalMedicine 2025" — a journal and a year with no title, authors or identifier to follow. Inside the intake, two further statistics appear with no source at all: that 80% of people are more attracted to leaner appearances, and that over 90% of patients report higher self-confidence after visible weight loss. None of this is drawn from the semaglutide or tirzepatide trials.
Is it selling FDA-approved drugs?
It offers access to them, and says so accurately: brand-name Ozempic, Wegovy and Zepbound are described as accessed through manufacturer programs — LillyDirect and NovoCare — with a separate GOAL.MD physician fee, and the site disclaims affiliation with Novo Nordisk and Eli Lilly by name. That is a different thing from calling its own compounded product FDA-approved, which it does not do; its footer says the opposite.
Which states does GOAL.MD serve?
Forty-eight, as a count rather than a list. Its homepage FAQ — behind a closed accordion you have to click open — reads: "We currently serve patients in 48 states across the US. Our telehealth platform allows you to receive care from licensed physicians no matter where you're located. Contact us to confirm availability in your specific state." Forty-eight means two states are excluded. Neither the forty-eight nor the two is named, and there is no state checker, so a prospective patient is asked to contact the company rather than being able to check an address before starting. This review names no excluded states, because naming them would mean inventing them.
Does GOAL.MD sell peptides?
Yes, two of them, and both are graded above. Sermorelin is $179 a month equivalent on a $537 charge for three months, or $199 month to month, sold "for muscle support & recovery". NAD+ is $249 a month, sold "for energy and longevity" — the most expensive thing GOAL.MD sells month to month. Both are marked Rx only, and the first question in its intake offers them as alternatives to weight loss. The evidence behind them is thin in different ways. There is no completed registry study of sermorelin at all: the 21 that come back on a search are tesamorelin, diagnostic stimulation tests and other molecules. Injected NAD+ has one randomized trial in a person, in heart failure. Neither is a reason to conclude anything about safety; both are reasons to read what the pages promise carefully.
Does sermorelin improve sleep?
Not in the closest thing to a trial of it, which is the specific reason this question is worth asking here. GOAL.MD's sermorelin page says "May improve sleep quality" and that "many patients report falling asleep faster and waking more rested within the first few weeks." The nearest randomized evidence is a 1997 placebo-controlled study in which nineteen adults aged 55 to 71 self-injected a GHRH(1-29) analog nightly for sixteen weeks. It measured sleep quality directly, using self-administered questionnaires, and reported it unaffected in both men and women. It did find increased lean body mass in the nine men, no change in the ten women, and increased skin thickness in both. One honest caveat: the molecule in that trial is a modified analog rather than sermorelin itself, because no randomized trial of sermorelin itself has measured any of this.
Compare
Others selling what GOAL.MD sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off GOAL.MD's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 6 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- US National Library of Medicine (2026). Sermorelin searched two ways on 2026-08-26. ClinicalTrials.gov returns 21 completed studies by intervention and NONE of them administers sermorelin — reading the intervention field of all 21, they are tesamorelin/TH9507 (9), unspecified GHRH used as a diagnostic stimulation test, GHRH 1-44, VRS-317 and octreotide. PubMed returns 19 records for sermorelin restricted to the randomized-controlled-trial publication type, the most recent published August 2005; narrowed to records also mentioning muscle, body composition, lean mass, sleep, recovery or skin, 3 remain. Note that the same PubMed search restricted to title and abstract returns 0, because the trial literature names the molecule GHRH(1-29)-NH2 rather than sermorelin. ClinicalTrials.gov and PubMed (US National Library of Medicine). https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- Khorram O, Laughlin GA, Yen SS (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. Journal of Clinical Endocrinology & Metabolism 82(5):1472-9 — single-blind, randomized, placebo-controlled; 10 women and 9 men aged 55-71, 16 weeks of nightly self-injection. Lean body mass rose in men only; skin thickness rose in both; body weight and body composition were otherwise unchanged; "sleep quality was unaffected in both genders". Note that the molecule tested is a norleucine-substituted GHRH(1-29) analog, not sermorelin itself. https://pubmed.ncbi.nlm.nih.gov/9141536/
- US National Library of Medicine (2026). PubMed search: ("nicotinamide adenine dinucleotide"[tiab] OR "NAD+"[tiab]) AND (subcutaneous[tiab] OR injection[tiab] OR intravenous[tiab]) AND randomized controlled trial[pt] — 4 records, run 2026-08-26. Only one administers NAD+ by an injected route; the other three are a 2012 phase 1 SIRT1-activator trial, a 2011 hypertonic-saline heart-failure study and a 2006 paper on ethanol elimination after intravenous amino acids. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=%28%22nicotinamide+adenine+dinucleotide%22%5Btiab%5D+OR+%22NAD%2B%22%5Btiab%5D%29+AND+%28subcutaneous%5Btiab%5D+OR+injection%5Btiab%5D+OR+intravenous%5Btiab%5D%29+AND+randomized+controlled+trial%5Bpt%5D
- Yu X, Xu J, Cao J, et al. (2026). Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial. American Journal of Cardiovascular Drugs 26(1):97-106 — the only randomized trial administering NAD+ by an injected route, in a heart-failure population. https://pubmed.ncbi.nlm.nih.gov/40954388/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.